Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients

This study has been completed.
Information provided by (Responsible Party):
Cellerix ( TiGenix S.A.U. ) Identifier:
First received: August 5, 2011
Last updated: March 5, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2013
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)